Pharmaceutical giant Merck & Co Inc said Monday it has applied for U.S. emergency use authorisation for its revolutionary drug to treat mild-to-moderate patients of COVID-19,
Pharmaceutical giant Merck & Co Inc said Monday it has applied for U.S. emergency use authorisation for its revolutionary drug to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease.
An authorisation from the U.S. Foo
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
